Rini BI - Search Results

1

Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.

Pal SK, McDermott DF, Atkins MB, Escudier B, Rini BI, Motzer RJ, Fong L, Joseph RW, Oudard S, Ravaud A, Bracarda S, Suárez C, Lam ET, Choueiri TK, Ding B, Quach C, Hashimoto K, Schiff C, Piault-Louis E, Powles T. Pal SK, et al. Among authors: rini bi. BJU Int. 2020 Jul;126(1):73-82. doi: 10.1111/bju.15058. Epub 2020 Apr 24. BJU Int. 2020. PMID: 32233107 Free PMC article. Clinical Trial.

2

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.

Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL; Cancer and Leukemia Group B. Rini BI, et al. Clin Cancer Res. 2004 Apr 15;10(8):2584-6. doi: 10.1158/1078-0432.ccr-03-0605. Clin Cancer Res. 2004. PMID: 15102658 Clinical Trial.

3

Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.

Rini BI, Sosman JA, Motzer RJ. Rini BI, et al. BJU Int. 2005 Aug;96(3):286-90. doi: 10.1111/j.1464-410X.2005.05616.x. BJU Int. 2005. Retraction in: BJU Int. 2012 Jun;109(11):E43. doi: 10.1111/j.1464-410X.2012.10613.x PMID: 16042715 Retracted. Review. No abstract available.

4

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI. Motzer RJ, et al. Among authors: rini bi. J Clin Oncol. 2006 Jan 1;24(1):16-24. doi: 10.1200/JCO.2005.02.2574. Epub 2005 Dec 5. J Clin Oncol. 2006. PMID: 16330672 Clinical Trial.

5

Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor.

Rini BI, Fong L, Weinberg V, Kavanaugh B, Small EJ. Rini BI, et al. J Urol. 2006 Jun;175(6):2087-91. doi: 10.1016/S0022-5347(06)00261-8. J Urol. 2006. PMID: 16697809

6

Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Rini BI, et al. Cancer. 2006 Jul 1;107(1):67-74. doi: 10.1002/cncr.21956. Cancer. 2006. PMID: 16736512 Free article. Clinical Trial.

7

Sunitinib in patients with metastatic renal cell carcinoma.

Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD. Motzer RJ, et al. Among authors: rini bi. JAMA. 2006 Jun 7;295(21):2516-24. doi: 10.1001/jama.295.21.2516. JAMA. 2006. PMID: 16757724 Clinical Trial.

8

A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.

Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. Lin AM, et al. Among authors: rini bi. BJU Int. 2006 Oct;98(4):763-9. doi: 10.1111/j.1464-410X.2006.06396.x. BJU Int. 2006. PMID: 16796694 Clinical Trial.

9

Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.

Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K, Simko J, Small EJ, Waldman FM. Rini BI, et al. BJU Int. 2006 Oct;98(4):756-62. doi: 10.1111/j.1464-410X.2006.06376.x. Epub 2006 Jul 7. BJU Int. 2006. PMID: 16827904

10

Laparoscopic versus open cytoreductive nephrectomy in advanced renal-cell carcinoma.

Eisenberg MS, Meng MV, Master VA, Stoller ML, Rini BI, Carroll PR, Kane CJ. Eisenberg MS, et al. Among authors: rini bi. J Endourol. 2006 Jul;20(7):504-8. doi: 10.1089/end.2006.20.504. J Endourol. 2006. PMID: 16859465

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

523 results

Search Page

Filters